Reneo Pharmaceuticals (OKUR) EBITDA (2020 - 2025)
Reneo Pharmaceuticals (OKUR) EBITDA from Mar 31, 2020 to Dec 31, 2025. The TTM Reneo Pharmaceuticals (OKUR) EBITDA is -$63M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Reneo Pharmaceuticals (OKUR) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +18.39% |
| 3 Years TTM | +5.15% |
| 5 Years TTM | +26.22% |
| All Time TTM | +24.31% |
Annual EBITDA change of Reneo Pharmaceuticals (OKUR)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$63M | +15.89% |
| 2024 | -$54M | +47.67% |
| 2023 | -$37M | -32.07% |
| 2022 | -$54M | +35.18% |
| 2021 | -$40M | +103.84% |
| 2020 | -$20M | N/A |
Comparison Reneo Pharmaceuticals (OKUR) five years EBITDA CAGR with competitors
Reneo Pharmaceuticals (OKUR) five years EBITDA CAGR is 26.21%.